Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 28, 2020
Daily News
May 28, 2020
- GSK’s Cost-Effectiveness Analysis for Trelegy Delayed, First Product under Full CEA Scheme
May 28, 2020
- Chuikyo Wary about Off-Year Price Survey amid COVID-19, Industry Officials Stress Concerns
May 28, 2020
- Nagasaki Univ. to Launch Clinical Trial for Nelfinavir for COVID-19
May 28, 2020
- Drug Makers Exploring “New Normal” in Post-COVID-19; Takeda Plans Major Changes
May 28, 2020
- Towa Voluntarily Recalls Pentasa Generics due to Inadequate Shipment Testing at Contract Manufacturer Nichi-Iko
May 28, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…